Laboratory Medicine ›› 2020, Vol. 35 ›› Issue (12): 1213-1219.DOI: 10.3969/j.issn.1673-8640.2020.12.003
Previous Articles Next Articles
YANG Wenjing1, LÜ Lihua1, YAO Jiayi1, WANG Hao1, ZHANG Chunyan2, WANG Beili1, PAN Baishen1, GUO Wei1()
Received:
2020-03-05
Online:
2020-12-30
Published:
2020-12-31
CLC Number:
YANG Wenjing, LÜ Lihua, YAO Jiayi, WANG Hao, ZHANG Chunyan, WANG Beili, PAN Baishen, GUO Wei. Role of exosome-derived circular RNA in tumor diagnosis and treatment[J]. Laboratory Medicine, 2020, 35(12): 1213-1219.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2020.12.003
生物功能 | circRNA名称 | 肿瘤类型 | 变化趋势 | 分子机制 | 临床参数分析 | 参考文献 |
---|---|---|---|---|---|---|
调控 细胞 增殖 | circRASSF2 | 喉鳞状细胞癌 | ↑ | miRNA-302b-3p/IGF-1R | T分期、淋巴结转移 | [10] |
circDB | HCC | ↑ | miRNA-34a/USP7/Cyclin A2 | [11] | ||
circIFT80 | 结直肠癌 | ↑ | miRNA-1236-3p/HOXB7 | 肿瘤分期、肿瘤大小、远处转移 | [12] | |
circFMN2 | 结直肠癌 | ↑ | miRNA-1182 | 肿瘤大小、肿瘤分期、远处转移、TNM分期 | [13] | |
circNRIP1 | 胃癌 | ↑ | miRNA-149-5p/AKT1/mTOR | 肿瘤大小、淋巴浸润 | [14] | |
circ_0044516 | 前列腺癌 | ↑ | miRNA-29a-3p | 肿瘤转移 | [15] | |
调控 侵袭 以及 转移 | circPTGR1 | HCC | ↑ | miRNA449a/MET | 临床分期、预后 | [16] |
circ_100338 | HCC | ↑ | HUVEC | 生存时间、TNM分期、血管侵犯、肺转移 | [17] | |
circCdr1as | HCC | ↑ | miRNA-1270/AFP | [18] | ||
circRanGAP1 | 胃癌 | ↑ | miRNA-877-3p/VEGFA | TNM分期、淋巴结转移、低生存率 | [19] | |
ciRS-133 | 胃癌 | ↑ | miRNA-133/PRDM16 | 白色脂肪组织褐变 | [20] | |
circPED8A | 胰腺癌 | ↑ | miRNA-338/MACC1/MET | 十二指肠浸润、血管浸润、T因子、TNM分 期、低生存率 | [21] | |
circIARS | 胰腺癌 | ↑ | miRNA-12/RhoA | 肝转移、脉管侵犯、TNM分期 | [22] | |
circPRMT5 | 膀胱尿路上皮癌 | ↑ | miRNA-30c/SNAIL1/ E-钙黏蛋白 | 淋巴结转移、晚期进展 | [23] | |
circPUM1 | 卵巢癌 | ↑ | miRNA-615-5p,miRNA-6753-5p | [24] | ||
circWHSC1 | 卵巢癌 | ↑ | miRNA-1182,miRNA-145 | [25] | ||
circ_0000677 | 结直肠癌 | ↑ | Wnt/β-catenin | [26] | ||
circ_0000284 | 胆管癌 | ↑ | miRNA-637/LY6E | 分化程度、TNM分期、淋巴结浸润 | [27] | |
调控 药物 耐药 | FECR1 | 小细胞肺癌 | ↑ | miRNA584-ROCK1 | 低生存率、化疗反应 | [28] |
circCdr1as | 卵巢癌 | ↓ | miRNA-1270 | 顺铂耐药 | [29] | |
circ_0000338 | 结直肠癌 | ↑ | / | 奥沙利铂耐药 | [30] | |
ciRS-122 | 结直肠癌 | ↑ | miRNA-122/M2-PK | 奥沙利铂耐药 | [31] |
生物功能 | circRNA名称 | 肿瘤类型 | 变化趋势 | 分子机制 | 临床参数分析 | 参考文献 |
---|---|---|---|---|---|---|
调控 细胞 增殖 | circRASSF2 | 喉鳞状细胞癌 | ↑ | miRNA-302b-3p/IGF-1R | T分期、淋巴结转移 | [10] |
circDB | HCC | ↑ | miRNA-34a/USP7/Cyclin A2 | [11] | ||
circIFT80 | 结直肠癌 | ↑ | miRNA-1236-3p/HOXB7 | 肿瘤分期、肿瘤大小、远处转移 | [12] | |
circFMN2 | 结直肠癌 | ↑ | miRNA-1182 | 肿瘤大小、肿瘤分期、远处转移、TNM分期 | [13] | |
circNRIP1 | 胃癌 | ↑ | miRNA-149-5p/AKT1/mTOR | 肿瘤大小、淋巴浸润 | [14] | |
circ_0044516 | 前列腺癌 | ↑ | miRNA-29a-3p | 肿瘤转移 | [15] | |
调控 侵袭 以及 转移 | circPTGR1 | HCC | ↑ | miRNA449a/MET | 临床分期、预后 | [16] |
circ_100338 | HCC | ↑ | HUVEC | 生存时间、TNM分期、血管侵犯、肺转移 | [17] | |
circCdr1as | HCC | ↑ | miRNA-1270/AFP | [18] | ||
circRanGAP1 | 胃癌 | ↑ | miRNA-877-3p/VEGFA | TNM分期、淋巴结转移、低生存率 | [19] | |
ciRS-133 | 胃癌 | ↑ | miRNA-133/PRDM16 | 白色脂肪组织褐变 | [20] | |
circPED8A | 胰腺癌 | ↑ | miRNA-338/MACC1/MET | 十二指肠浸润、血管浸润、T因子、TNM分 期、低生存率 | [21] | |
circIARS | 胰腺癌 | ↑ | miRNA-12/RhoA | 肝转移、脉管侵犯、TNM分期 | [22] | |
circPRMT5 | 膀胱尿路上皮癌 | ↑ | miRNA-30c/SNAIL1/ E-钙黏蛋白 | 淋巴结转移、晚期进展 | [23] | |
circPUM1 | 卵巢癌 | ↑ | miRNA-615-5p,miRNA-6753-5p | [24] | ||
circWHSC1 | 卵巢癌 | ↑ | miRNA-1182,miRNA-145 | [25] | ||
circ_0000677 | 结直肠癌 | ↑ | Wnt/β-catenin | [26] | ||
circ_0000284 | 胆管癌 | ↑ | miRNA-637/LY6E | 分化程度、TNM分期、淋巴结浸润 | [27] | |
调控 药物 耐药 | FECR1 | 小细胞肺癌 | ↑ | miRNA584-ROCK1 | 低生存率、化疗反应 | [28] |
circCdr1as | 卵巢癌 | ↓ | miRNA-1270 | 顺铂耐药 | [29] | |
circ_0000338 | 结直肠癌 | ↑ | / | 奥沙利铂耐药 | [30] | |
ciRS-122 | 结直肠癌 | ↑ | miRNA-122/M2-PK | 奥沙利铂耐药 | [31] |
名称 | 肿瘤类型 | 研究对象 | 标本类型 | 趋势 | 临床参数分析 | AUC | 敏感性/% | 特异性/% | 参考文献 | |
---|---|---|---|---|---|---|---|---|---|---|
病例数 | 对照例数 | |||||||||
circ_0004771 | 结直肠癌 | 110 | 35(HC) | 血清 | ↑ | TNM分期、远处转移 | 0.88 | 80.91 | 82.86 | [36] |
circHIPK3 | 结直肠癌 | 20 | 20(HC) | 血清 | ↑ | 0.771 | 71 | 80 | [37] | |
circ_0065149 | EGC | 39 | 41(HC) | 血浆 | ↓ | 肿瘤大小、外周神经侵袭 | 0.64 | 48.7 | 90.2 | [38] |
circ_0051443 | HCC | 60 | 60(HC) | 血浆 | ↓ | 肝硬化 | 0.808 9 | [39] | ||
FECR1 | 小细胞肺癌 | 61 | 55(HC) | 血清 | ↑ | 低生存率、化疗反应 | [31] | |||
circ_002178 | 肺腺癌 | 120 | 30(HC) | 血清 | ↑ | 0.996 7 | [40] | |||
circ_0001492、 circ_0001346 | 肺腺癌 | 15 | 15(HC) | 血浆 | ↑ | [41] | ||||
circ_00005795、 circ_0088088 | 乳腺癌 | 8 | 8(HC) | 血清 | ↓ ↑ | [42-43] | ||||
circ_0000284 | 胆管癌 | 25 | 25(HC) | 血浆 | ↑ | 肿瘤分化程度、TNM分 期、淋巴结浸润 | [27] | |||
名称 | 肿瘤类型 | 研究对象 | 标本类型 | 趋势 | 临床参数分析 | AUC | 敏感性/% | 特异性/% | 参考文献 | |
病例数 | 对照例数 | |||||||||
circPED8A | 胰腺癌 | 93 | 20(HC) | 血浆 | ↑ | 十二指肠浸润、血管浸 润、T因子、TNM分 期、低生存率 | [21] | |||
circIARS | 胰腺癌 | 20(伴转移) | 20(不伴转 移) | 血浆 | ↑ | 肝转移、脉管侵犯、TNM 分期 | [22] | |||
circ_0044516 | 前列腺癌 | 6 | 6(HC) | 血液 | ↑ | [15] | ||||
circPRMT5 | 膀胱尿路上 皮癌 | 血清:71 尿液:18 | 血清:35 (HC) 尿液:18 (HC) | 血清尿液 | ↑ | 淋巴结转移、晚期肿瘤进 展 | [23] | |||
circ_0109046、 circ_0002577 | 子宫内膜癌 | 10 | 10(HC) | 血清 | ↑ ↑ | [44] | ||||
circ_007293、 circ_031752、 circ_020135 | 甲状腺乳 头状癌 | 3 | 3(良性甲 状腺肿) | 血清 | ↑ ↑ ↓ | [45] | ||||
circ_0001946、 circ_0043603 | 食管鳞状 细胞癌 | 50 | 50 (HC) | 血浆 | ↓ | 预后 | 0.928 | 84 | 89 | [46] |
名称 | 肿瘤类型 | 研究对象 | 标本类型 | 趋势 | 临床参数分析 | AUC | 敏感性/% | 特异性/% | 参考文献 | |
---|---|---|---|---|---|---|---|---|---|---|
病例数 | 对照例数 | |||||||||
circ_0004771 | 结直肠癌 | 110 | 35(HC) | 血清 | ↑ | TNM分期、远处转移 | 0.88 | 80.91 | 82.86 | [36] |
circHIPK3 | 结直肠癌 | 20 | 20(HC) | 血清 | ↑ | 0.771 | 71 | 80 | [37] | |
circ_0065149 | EGC | 39 | 41(HC) | 血浆 | ↓ | 肿瘤大小、外周神经侵袭 | 0.64 | 48.7 | 90.2 | [38] |
circ_0051443 | HCC | 60 | 60(HC) | 血浆 | ↓ | 肝硬化 | 0.808 9 | [39] | ||
FECR1 | 小细胞肺癌 | 61 | 55(HC) | 血清 | ↑ | 低生存率、化疗反应 | [31] | |||
circ_002178 | 肺腺癌 | 120 | 30(HC) | 血清 | ↑ | 0.996 7 | [40] | |||
circ_0001492、 circ_0001346 | 肺腺癌 | 15 | 15(HC) | 血浆 | ↑ | [41] | ||||
circ_00005795、 circ_0088088 | 乳腺癌 | 8 | 8(HC) | 血清 | ↓ ↑ | [42-43] | ||||
circ_0000284 | 胆管癌 | 25 | 25(HC) | 血浆 | ↑ | 肿瘤分化程度、TNM分 期、淋巴结浸润 | [27] | |||
名称 | 肿瘤类型 | 研究对象 | 标本类型 | 趋势 | 临床参数分析 | AUC | 敏感性/% | 特异性/% | 参考文献 | |
病例数 | 对照例数 | |||||||||
circPED8A | 胰腺癌 | 93 | 20(HC) | 血浆 | ↑ | 十二指肠浸润、血管浸 润、T因子、TNM分 期、低生存率 | [21] | |||
circIARS | 胰腺癌 | 20(伴转移) | 20(不伴转 移) | 血浆 | ↑ | 肝转移、脉管侵犯、TNM 分期 | [22] | |||
circ_0044516 | 前列腺癌 | 6 | 6(HC) | 血液 | ↑ | [15] | ||||
circPRMT5 | 膀胱尿路上 皮癌 | 血清:71 尿液:18 | 血清:35 (HC) 尿液:18 (HC) | 血清尿液 | ↑ | 淋巴结转移、晚期肿瘤进 展 | [23] | |||
circ_0109046、 circ_0002577 | 子宫内膜癌 | 10 | 10(HC) | 血清 | ↑ ↑ | [44] | ||||
circ_007293、 circ_031752、 circ_020135 | 甲状腺乳 头状癌 | 3 | 3(良性甲 状腺肿) | 血清 | ↑ ↑ ↓ | [45] | ||||
circ_0001946、 circ_0043603 | 食管鳞状 细胞癌 | 50 | 50 (HC) | 血浆 | ↓ | 预后 | 0.928 | 84 | 89 | [46] |
[1] | BRAICU C,TOMULEASA C,MONROIG P,et al.Exosomes as divine messengers:are they the Hermes of modern molecular oncology?[J]. Cell Death Differ,2015,22(1):34-45. |
[2] | MENG X,LI X,ZHANG P,et al.Circular RNA:an emerging key player in RNA world[J]. Brief Bioinform,2017,18(4):547-557. |
[3] | LI Y,ZHENG Q,BAO C,et al.Circular RNA is enriched and stable in exosomes:a promising biomarker for cancer diagnosis[J]. Cell Res,2015,25(8):981-984. |
[4] | XU R,RAI A,CHEN M,et al.Extracellular vesicles in cancer - implications for future improvements in cancer care[J]. Nat Rev Clin Oncol,2018,15(10):617-638. |
[5] | KALLURI R,LEBLEU V S. The biology,function,and biomedical applications of exosomes[J]. Science,2020,367(6478):eaau6977. |
[6] | LI X,WANG X.The emerging roles and therapeutic potential of exosomes in epithelial ovarian cancer[J]. Mol Cancer,2017,16(1):92. |
[7] | JECK W R,SORRENTINO J A,WANG K,et al.Circular RNAs are abundant,conserved,and associated with ALU repeats[J]. RNA,2013,19(2):141-157. |
[8] | SU M,XIAO Y,MA J,et al.Circular RNAs in cancer:emerging functions in hallmarks,stemness,resistance and roles as potential biomarkers[J]. Mol Cancer,2019,18(1):90. |
[9] | WANG Y,LIU J,MA J,et al.Exosomal circRNA:biogenesis,effect and application in human diseases[J]. Mol Cancer,2019,18(1):116. |
[10] | TIAN L,CAO J,JIAO H,et al.CircRASSF2 promotes laryngeal squamous cell carcinoma progression by regulating the miRNA-302b-3p/IGF-1R axis[J]. Clin Sci(Lond),2019,133(9):1053-1066. |
[11] | ZHANG H,DENG T,GE S,et al.Exosome circRNA secreted from adipocytes promotes the growth of hepatocellular carcinoma by targeting deubiquitination-related USP7[J]. Oncogene,2019,38(15):2844-2859. |
[12] | FENG W,GONG H,WANG Y,et al.circIFT80 functions as a ceRNA of miRNA-1236-3p to promote colorectal cancer progression[J]. Mol Ther Nucleic Acids,2019,18:375-387. |
[13] | LI Y,LI C,XU R,et al.A novel circFMN2 promotes tumor proliferation in CRC by regulating the miR-1182/hTERT signaling pathways[J]. Clin Sci(Lond),2019,133(24):2463-2479. |
[14] | ZHANG X,WANG S,WANG H,et al.Circular RNA circNRIP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1/mTOR pathway[J]. Mol Cancer,2019,18(1):20. |
[15] | LI T,SUN X,CHEN L.Exosome circ_0044516 promotes prostate cancer cell proliferation and metastasis as a potential biomarker[J]. J Cell Biochem,2020,121(3):2118-2126. |
[16] | WANG G,LIU W,ZOU Y,et al.Three isoforms of exosomal circPTGR1 promote hepatocellular carcinoma metastasis via the miRNA449a-MET pathway[J]. EBioMedicine,2019,40:432-445. |
[17] | HUANG X Y,HUANG Z L,HUANG J,et al.Exosomal circRNA-100338 promotes hepatocellular carcinoma metastasis via enhancing invasiveness and angiogenesis[J]. J Exp Clin Cancer Res,2020,39(1):20. |
[18] | SU Y,LV X,YIN W,et al.CircRNA Cdr1as functions as a competitive endogenous RNA to promote hepatocellular carcinoma progression[J]. Aging(Albany NY),2019,11(19):8182-8203. |
[19] | LU J,WANG Y H,YOON C,et al.Circular RNA circ-RanGAP1 regulates VEGFA expression by targeting miR-877-3p to facilitate gastric cancer invasion and metastasis[J]. Cancer Lett,2020,471:38-48. |
[20] | ZHANG H,ZHU L,BAI M,et al.Exosomal circRNA derived from gastric tumor promotes white adipose browning by targeting the miR-133/PRDM16 pathway[J]. Int J Cancer,2019,144(10):2501-2515. |
[21] | LI Z,YANFANG W,LI J,et al.Tumor-released exosomal circular RNA PDE8A promotes invasive growth via the miR-338/MACC1/MET pathway in pancreatic cancer[J]. Cancer Lett,2018,432:237-250. |
[22] | LI J,LI Z,JIANG P,et al.Circular RNA IARS(circ-IARS) secreted by pancreatic cancer cells and located within exosomes regulates endothelial monolayer permeability to promote tumor metastasis[J]. J Exp Clin Cancer Res,2018,37(1):177. |
[23] | CHEN X,CHEN R X,WEI W S,et al.PRMT5 circular rna promotes metastasis of urothelial carcinoma of the bladder through sponging miRNA-30c to induce epithelial-mesenchymal transition[J]. Clin Cancer Res,2018,24(24):6319-6330. |
[24] | GUAN X,ZONG Z H,LIU Y,et al.circPUM1 promotes tumorigenesis and progression of ovarian cancer by sponging miR-615-5p and miR-6753-5p[J]. Mol Ther Nucleic Acids,2019,18:882-892. |
[25] | ZONG Z H,DU Y P,GUAN X,et al.CircWHSC1 promotes ovarian cancer progression by regulating MUC1 and hTERT through sponging miR-145 and miR-1182[J]. J Exp Clin Cancer Res,2019,38(1):437. |
[26] | ZHAO H,CHEN S,FU Q.Exosomes from CD133+ cells carrying circ-ABCC1 mediate cell stemness and metastasis in colorectal cancer[J]. J Cell Biochem,2020,121(5-6):3286-3297. |
[27] | WANG S,HU Y,LV X,et al.Circ-0000284 arouses malignant phenotype of cholangiocarcinoma cells and regulates the biological functions of peripheral cells through cellular communication[J]. Clin Sci(Lond),2019,133(18):1935-1953. |
[28] | LI L,LI W,CHEN N,et al.FLI1 exonic circular RNAs as a novel oncogenic driver to promote tumor metastasis in small cell lung cancer[J]. Clin Cancer Res,2019,25(4):1302-1317. |
[29] | ZHAO Z,JI M,WANG Q,et al.Circular RNA cdr1as upregulates scai to suppress cisplatin resistance in ovarian cancer via miR-1270 suppression[J]. Mol Ther Nucleic Acids,2019,18:24-33. |
[30] | HON K W,AB-MUTALIB N S,ABDULLAH N M A,et al. Extracellular vesicle-derived circular RNAs confers chemoresistance in colorectal cancer[J]. Sci Rep,2019,9(1):16497. |
[31] | WANG X,ZHANG H,YANG H,et al.Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer[J]. Mol Oncol,2020,14(3):539-555. |
[32] | DAI X,CHEN C,YANG Q,et al.Exosomal circRNA_100284 from arsenite-transformed cells,via microRNA-217 regulation of EZH2,is involved in the malignant transformation of human hepatic cells by accelerating the cell cycle and promoting cell proliferation[J]. Cell Death Dis,2018,9(5):454. |
[33] | QIN W,TSUKASAKI Y,DASGUPTA S,et al.Exosomes in human breast milk promote EMT[J]. Clin Cancer Res,2016,22(17):4517-4524. |
[34] | ZHENG P,CHEN L,YUAN X,et al.Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells[J]. J Exp Clin Cancer Res,2017,36(1):53. |
[35] | DOU Y,CHA D J,FRANKLIN J L,et al.Circular RNAs are down-regulated in KRAS mutant colon cancer cells and can be transferred to exosomes[J]. Sci Rep,2016,6:37982. |
[36] | PAN B,QIN J,LIU X,et al.Identification of serum exosomal hsa-circ-0004771 as a novel diagnostic biomarker of colorectal cancer[J]. Front Genet,2019,10:1096. |
[37] | BARBAGALLO C,BREX D,CAPONNETTO A,et al.LncRNA UCA1,upregulated in CRC biopsies and downregulated in serum exosomes,controls mRNA expression by RNA-RNA interactions[J]. Mol Ther Nucleic Acids,2018,12:229-241. |
[38] | SHAO Y,TAO X,LU R,et al.Hsa_circ_0065149 is an indicator for early gastric cancer screening and prognosis prediction[J]. Pathol Oncol Res,2020,26(3):1475-1482. |
[39] | CHEN W,QUAN Y,FAN S,et al.Exosome-transmitted circular RNA hsa_circ_0051443 suppresses hepatocellular carcinoma progression[J]. Cancer Lett,2020,475:119-128. |
[40] | WANG J,ZHAO X,WANG Y,et al.circRNA-002178 act as a ceRNA to promote PDL1/PD1 expression in lung adenocarcinoma[J]. Cell Death Dis,2020,11(1):32. |
[41] | CHEN F,HUANG C,WU Q,et al.Circular RNAs expression profiles in plasma exosomes from early-stage lung adenocarcinoma and the potential biomarkers[J]. J Cell Biochem,2020,121(3):2525-2533. |
[42] | YANG S J,WANG D D,ZHOU S Y,et al.Identification of circRNA-miRNA networks for exploring an underlying prognosis strategy for breast cancer[J]. Epigenomics,2020,12(2):101-125. |
[43] | WANG J,ZHANG Q,ZHOU S,et al.Circular RNA expression in exosomes derived from breast cancer cells and patients[J]. Epigenomics,2019,11(4):411-421. |
[44] | XU H,GONG Z,SHEN Y,et al.Circular RNA expression in extracellular vesicles isolated from serum of patients with endometrial cancer[J]. Epigenomics,2018,10(2):187-197. |
[45] | YANG C,WEI Y,YU L,et al.Identification of altered circular RNA expression in serum exosomes from patients with papillary thyroid carcinoma by high-throughput sequencing[J]. Med Sci Monit,2019,25:2785-2791. |
[46] | FAN L,CAO Q,LIU J,et al.Circular RNA profiling and its potential for esophageal squamous cell cancer diagnosis and prognosis[J]. Mol Cancer,2019,18(1):16. |
[1] | ZHOU Yunlan, SHEN Lisong. Clinical application and challenges of liquid biopsy biomarkers in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(9): 807-811. |
[2] | PENG Wei, LI Yungai, XU Jing, LIU Hua, YANG Cuixia, SHEN Yunyue. Serum inflammatory factors combined with PSA and f-PSA in the auxiliary diagnosis of prostate cancer [J]. Laboratory Medicine, 2023, 38(9): 849-854. |
[3] | DING Xiaoyuan, DAI Jinsheng, JIAO Ronghong, MA Suli, ZHU Haifeng, WU Mengya, CHE Yanran, ZHANG Lei. Influence of obesity/overweight on inflammatory factors of Th1/Th2 and Th17/Treg in children with asthma attacks [J]. Laboratory Medicine, 2023, 38(8): 748-752. |
[4] | CHEN Wenju, ZHOU Yong, XU Jiajia, WANG Pan. Role of serum exosomal miR-23b-3p and miR-4429 in patients with hepatocellular carcinoma [J]. Laboratory Medicine, 2023, 38(7): 624-628. |
[5] | ZHANG Min, WANG Binyu, CHI Weiqun, LIU Yu. Research progress of exosomal non-coding RNA as biomarkers for disease diagnosis [J]. Laboratory Medicine, 2023, 38(6): 594-598. |
[6] | ZHAO Jing, WANG Pei, LU Dandan, QI Dandan, LI Xuan. Expression levels of serum miR-4443 and TRAF4 in patients with hemorrhagic stroke [J]. Laboratory Medicine, 2023, 38(5): 413-418. |
[7] | GAO Feng. Clinical application of novel tumor biomarkers:prospects and challenges [J]. Laboratory Medicine, 2023, 38(4): 303-306. |
[8] | SONG Shiwei, LI Jingwu, LIN Tao, LIU Zeyu, WANG Zhiqiang, SUN Weidong. Relationship between GPNMB and non-small cell lung cancer immune infiltration and prognosis [J]. Laboratory Medicine, 2023, 38(4): 347-351. |
[9] | WU Jiong, HU Jiahua, SHI Meifang, LIU Tao, DAI Jie, LU Xinyi, ZOU Zheng. Research progress of biomarkers of prostate cancer [J]. Laboratory Medicine, 2023, 38(2): 190-195. |
[10] | QIAN Linyu, LIANG Weifang, TANG Sichen. Determination and clinical significance of NLRP3,CTRP6 and IL-1β in patients with gestational diabetes mellitus [J]. Laboratory Medicine, 2023, 38(10): 936-940. |
[11] | WU Yating, LI Zhuolin, LEI Yan, JIA Ruxue, ZHANG Shenghang, WANG Shuiliang. Research progress of miRNA in urine as a biomarker for common malignant tumors [J]. Laboratory Medicine, 2023, 38(1): 94-99. |
[12] | KONG Yujie, WANG Chen, HE Bing. Research progress of N6-methyladenosine in biological function and detection technology [J]. Laboratory Medicine, 2022, 37(9): 872-876. |
[13] | WANG Rui, LI Zhaoyan, ZHAO Aiguang. Application of circulating tumor DNA detection in the diagnosis and treatment of gastric cancer [J]. Laboratory Medicine, 2022, 37(9): 877-881. |
[14] | DUAN Yuping, XIE Li, CAI Leiming, WU Jingjing, HONG Mao, LI Qian. Correlation of serum exosomes,placental exosomes and exosomal miR-210 with preeclampsia [J]. Laboratory Medicine, 2022, 37(8): 715-719. |
[15] | LIU Xingqiang, NING Lifen, LI Lin, CHEN Zhongcheng. Correlation of lung cancer clinicopathological characteristics with FR+-CTC,ANXA2 and ProGRP [J]. Laboratory Medicine, 2022, 37(8): 735-740. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||